Acceptability of Artificial Intelligence in the Diagnosis of Prostate Cancer
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE · Jul 10, 2025
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This study is looking at how comfortable patients with early-stage prostate cancer and their healthcare providers feel about using artificial intelligence (AI) to help diagnose the disease. It also explores whether patients are willing to share their health information to help improve AI tools. AI has the potential to make diagnoses more accurate and personalized, but it’s important to understand if people are open to using it in real-life healthcare.
Men over 18 who have been diagnosed with localized (early-stage) prostate cancer may be eligible to join the study. Participants will be asked to complete an online questionnaire about their thoughts on AI and sharing health data. The study is taking place in Belgium, Italy, and Spain, and all personal information will be kept private and secure. If you’re interested in helping researchers understand how AI might be used in prostate cancer diagnosis, this study might be a good fit.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • over 18 years;
- • with diagnose of localized prostate cancer;
- • consent to the study.
- Exclusion Criteria:
- • not speaking French;
- • diagnosed with metastatic cancer from the outset;
- • terminally ill;
- • people suffering from mental retardation, dementia or altered state of consciousness.
About Centre Hospitalier Universitaire De Liege
The Centre Hospitalier Universitaire de Liège (CHU Liège) is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative clinical research and comprehensive patient care. As a prominent sponsor of clinical trials, CHU Liège integrates cutting-edge scientific inquiry with clinical practice, fostering an environment that enhances the development of new therapies and medical interventions. With a multidisciplinary team of experienced researchers and healthcare professionals, the institution is dedicated to improving patient outcomes and contributing to the global body of medical knowledge. CHU Liège emphasizes collaboration with industry partners and academic institutions to drive excellence in clinical research and support the translation of findings into real-world applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Liège, , Belgium
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported